Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine as adjunctive therapy in schizophrenia
NCT00999505Phase 3Unknown
- Sponsor
- Hospital de Clínicas de Porto Alegre
- Start
- May 2010
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amantadine in schizophrenia, sponsored by Hospital de Clínicas de Porto Alegre. Primary endpoint: Brief Psychiatric Rating Scale at 12 weeks. Status: unknown.
02
Drugs
amantadine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00999505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00999505.